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Background-—Peripheral arterial disease (PAD) shares several risk factors with atrial ﬁbrillation (AF), and persons with PAD have an
increased risk of stroke. It is unclear if PAD is associated with an increased risk for AF and whether this potential association
explains the increased risk of stroke observed in those with PAD.
Methods and Results-—We examined the association between PAD, measured by ankle-brachial index (ABI), and incident AF and
incident stroke, separately, in 6568 participants (mean age 6210 years, 53% women, 62% nonwhite) from the Multi-Ethnic Study of
Atherosclerosis (MESA). ABI values <1.0 or >1.4 deﬁned PAD. AF was ascertained through review of hospital discharge records and
from Medicare claims data until December 31, 2010. An independent adjudication committee ascertained stroke events. Cox
regression was used to estimate hazard ratios and 95% CIs for the association between PAD and AF and stroke. Over a median
follow-up of 8.5 years, 301 (4.6%) participants developed AF and 140 (2.1%) developed stroke. In a model adjusted for
sociodemographics, cardiovascular risk factors, and potential confounders, PAD was associated with an increased risk of AF (hazard
ratio 1.5, 95% CI 1.1 to 2.0). In a similar model, PAD was associated with incident stroke (hazard ratio 1.7, 95% CI 1.1 to 2.5), and the
magnitude of risk was not different after inclusion of AF as a time-dependent covariate (hazard ratio 1.7, 95% CI 1.1 to 2.5).
Conclusions-—PAD is associated with an increased risk of AF and stroke in MESA. Potentially, the relationship between PAD and
stroke is not mediated by AF. ( J Am Heart Assoc. 2014;3:e001270 doi: 10.1161/JAHA.114.001270)
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P eripheral arterial disease (PAD) and atrial ﬁbrillation(AF) share several common risk factors, including
diabetes and smoking.1–3 In the Women’s Health Initiative
Study, PAD was independently associated with the develop-
ment of AF among postmenopausal women.4 However, the
association of PAD deﬁned by the ankle-brachial index (ABI)
and incident AF has not been examined in men or in middle-
aged women of diverse racial and ethnic backgrounds.
Similarly, PAD and stroke share common risk factors. An
increased risk of PAD has been reported in patients with
stroke and an increased risk of stroke has been shown in
patients with PAD.5–10 It is well established that PAD
independently predicts stroke in patients with AF and
consequently has been included as 1 of the components
of the CHA2DS2-VASc (congestive heart failure, hyperten-
sion, age ≥75 years, diabetes mellitus, and prior stroke or
transient ischemic attack–vascular disease/sex category)
score.11–13 Furthermore, ischemic stroke triples the mortal-
ity rate among patients with AF compared with AF patients
who do not experience stroke.14
Potentially, these commonalities among PAD, AF, and
stroke reﬂect shared pathophysiologic states in which each
condition inﬂuences the development of the other. Therefore,
we examined the association between PAD and incident AF
and stroke in the Multi-Ethnic Study of Atherosclerosis
(MESA). We also investigated whether the association
between PAD and stroke is mediated by AF.
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Details of MESA have been reported previously.15 Brieﬂy,
between July 2000 and September 2002, 6814 participants
were recruited at 6 ﬁeld centers (Baltimore, MD; Chicago, IL;
Forsyth County, NC; Los Angeles, CA; New York, NY; and St.
Paul, MN) in the United States. The institutional review board
at each site approved the study and each participant gave
informed consent at the time of enrollment. Requirement for
study participation included age between 45 and 84 years
and no history of clinical cardiovascular disease. For the
purpose of this analysis, participants were excluded if they did
not undergo baseline ABI measurement, baseline character-
istics were not recorded, and/or follow-up data regarding AF
or stroke were missing. Additionally, baseline cases of AF
were excluded to examine incident AF.
Of the 6814 participants enrolled in MESA, we excluded 58
participants who had a diagnosis of AF before enrollment. The
majority of these cases were detected by Medicare linkage,
and only 1 case was present in the baseline electrocardio-
gram. Of those who remained, 6 participants with missing
follow-up data, 77 participants with missing ABI data, and 105
participants with either missing baseline characteristics or
missing medication data also were excluded. After all
exclusions (n=246), 6568 participants (mean age 6210
years, 53% women, 38% whites, 27% blacks, 22% Hispanics,
and 12% Chinese Americans) remained and were included in
the ﬁnal analysis.
Baseline Characteristics
Participant characteristics recorded during the initial
MESA visit were used in this analysis. Age, sex, race/
ethnicity, income, and education were self-reported. Annual
income was categorized into 3 levels (<$20 000, $20 000 to
$49 999, and ≥$50 000). Similarly, education was catego-
rized into “high school or less,” “some college,” and “college
or more.” Smoking was deﬁned as current or former smoker.
Blood samples were obtained after a 12-hour fast. Serum
measurements of total cholesterol, high-density lipoprotein
(HDL) cholesterol, plasma glucose, and high-sensitivity C-
reactive protein (hs-CRP) were used in this analysis. Diabetes
was deﬁned as a fasting glucose value ≥126 mg/dL or a
history of diabetes medication use. After the participant
rested for 5 minutes in a seated position, blood pressure was
measured 3 separate times and the mean of the last 2 values
was used. The use of aspirin, statins, and antihypertensive
and lipid-lowering medications was self-reported. Body mass
index was computed as the weight in kilograms divided by the
square of the height in meters. Left ventricular hypertrophy
was deﬁned by the Cornell criteria (R-wave amplitude AVL plus
S-wave amplitude V3 ≥2800 mm for men and ≥2000 mm for
women) using electrocardiographic data.16
Peripheral Arterial Disease
Systolic blood pressures were measured in both the right and
left brachial, posterior tibial, and dorsalis pedis arteries with
Doppler instruments. The average of the measurements was
used to calculate ABI for each side. Consistent with current
guidelines, a value of <1.0 or >1.4 deﬁned PAD.10,17 In a
secondary analysis, we examined the association of low (<1.0)
and high (>1.4) ABI values (referent group 1.0≤ABI≤1.4)
separately with AF. Additionally, the association of ABI as a
continuous variable with AF was examined and is presented
as the risk of AF with decreasing ABI values by decrements of
0.1 after excluding participants with ABI values >1.4.
Atrial Fibrillation
Follow-up phone calls to study participants every 9 to
12 months were used to identify hospitalizations and medical
records, including discharge diagnoses. Additionally, for par-
ticipants 65 years or older enrolled in fee-for-service Medicare,
Medicare claims data were used to identify inpatient AF cases.
Incident AF was deﬁned by International Classiﬁcation of
Disease, Ninth Revision codes 427.31 or 427.32.
Stroke
Trained personnel abstracted medical records to identify
possible stroke events. Two physicians from the MESA Events
Committee independently reviewed medical records for end
point classiﬁcation and assignment of event dates. If the
reviewing physicians disagreed on the event classiﬁcation,
they adjudicated differences. If disagreements persisted, the
full Events Committee made the ﬁnal classiﬁcation. Stroke
was classiﬁed as a dichotomous variable (present or absent)
and was deﬁned by the rapid onset of documented focal
neurologic deﬁcits lasting ≥24 hours or until death.15 If
symptoms were present for <24 hours, a clinically relevant
lesion on brain imaging must have been present for stroke to
be documented as present. Due to the small number of
documented cases of stroke (n=140), we grouped hemor-
rhages (eg, subarachnoid, intraparenchymal) and infarcts into
1 category.
Statistical Analysis
Categorical variables were reported as frequency and
percentage, while continuous variables were recorded as
meanstandard deviation (SD). Statistical signiﬁcance for
categorical variables was tested using the v2 method and
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the Wilcoxon rank-sum procedure for continuous variables.
Kaplan–Meier estimates were used to compute cumulative
incidence of AF by PAD, and the difference in estimates
was compared by using the log-rank procedure.18 Follow-up
time was deﬁned as the time between the initial study visit
until the diagnosis of AF, loss to follow-up, death, or end of
follow-up, which was December 31, 2010. Cox proportional
hazards regression was used to compute hazard ratios
(HRs) and 95% conﬁdence intervals (CI) for the association
between PAD and AF. Multivariable models were con-
structed with incremental adjustments as follows: Model 1
adjusted for age, sex, race/ethnicity, income, and educa-
tion; Model 2 adjusted for Model 1 covariates plus smoking
status, systolic blood pressure, diabetes, body mass index,
total cholesterol, HDL cholesterol, aspirin, antihypertensive
and lipid-lowering medications, hs-CRP levels, and left
ventricular hypertrophy. Using similar models, we also
examined the association between PAD and stroke with
and without AF to explore the attenuating effect of AF on
stroke among participants with PAD by adjusting for AF as
a time-dependent covariate. Although there were a small
number of stroke events (n=140), ischemic strokes repre-
sented the majority (n=116, 83%) and a sensitivity analysis
was performed examining the mediation of AF on the
association of PAD with ischemic strokes. We tested for
interactions between our main effect variable and age, sex,
and race/ethnicity. We also constructed a restricted cubic
spline model to examine the graphical relationship between
ABI and the risk for AF and stroke, and incorporated knots
at the 5th, 50th, and 95th percentiles.19 The proportional
hazards assumption was not violated in our analysis.
Statistical signiﬁcance was deﬁned as P<0.05. SAS Version
9.3 (SAS Institute Inc) was used for all analyses.
Results
A total of 774 (12%) study participants had baseline PAD.
Baseline characteristics for study participants stratiﬁed by
PAD status are shown in Table 1. Participants with PAD were
more likely to be older and female, to have a high school
diploma or less, and to have an annual income <$20 000 than
participants without PAD. A higher percentage of black
participants (17%) had PAD than other races (11% whites,
7.8% Hispanics, 8.1% Chinese Americans; P<0.0001). PAD
participants also were more likely to smoke, to have diabetes,
and to have higher values for systolic blood pressure, HDL
cholesterol, and hs-CRP. Additionally, participants with PAD
were more likely to report using statins and antihypertensive
and lipid-lowering medications.
During a median follow-up of 8.5 years, 301 (4.6%)
participants developed AF. AF incidence rates per 1000
person-years were 12 (95% CI 9.5 to 15.4) for participants
with PAD compared with 5.3 (95% CI 4.6 to 6.0) for
participants without PAD. Figure 1 shows the unadjusted
cumulative incidence curves for AF by PAD (log-rank
P<0.0001).
Participants with PAD had twice the risk of AF in an
unadjusted Cox regression model (HR 2.3, 95% CI 1.8 to 3.0).
The HR remained signiﬁcant after adjustment for sociodemo-
graphics, cardiovascular risk factors, and potential confound-
ers, and the results were consistent across subgroups
stratiﬁed by age, sex, and race/ethnicity (Table 2). Expanding
the demographic model to include ﬁeld center and expanding
the smoking variable to include pack-years did not change the
result (HR 1.5, 95% CI 1.1 to 2.0).
The associations between AF and high (>1.4) and low
(<1.0) ABI values were examined separately and were in the
same direction as the main result for PAD (ABI <1.0, adjusted
HR 1.5, 95% CI 1.1 to 2.0; ABI >1.4, adjusted HR 1.8, 95% CI
0.65 to 4.8). The result for ABI values >1.4 was not signiﬁcant
due to the small number of participants in this group (n=40)
and consequently a small number of AF cases (n=4). The HR
for ABI as a continuous variable, decreasing by 0.1, was 1.1
(95% CI 1.04 to 1.2) after excluding participants with ABI
values >1.4.
Incident stroke occurred in 140 (2.1%) participants. Only
36 (26%) cases of stroke had PAD, and of these, only 1 (2.8%)
had a diagnosis of AF before stroke. Table 3 shows the HR for
stroke among participants with PAD compared with those
without PAD. Additionally, HRs are shown with and without AF
as a time-dependent covariate. In a sociodemographically
adjusted model, PAD was associated with twice the risk of
stroke compared with no PAD. The magnitude of the
association did not substantively change with the addition
of AF. A similar result was observed when the association
between PAD and stroke was examined in a model further
adjusted for cardiovascular risk factors and potential con-
founders (Table 3). A sensitivity analysis including only
ischemic strokes showed a trend for the association between
PAD and stroke (HR 1.5, P=0.071). The addition of AF to this
model did not substantively alter our ﬁndings (HR 1.5,
P=0.060).
Figure 2 shows the association between ABI values and
incident AF and stroke using a restricted cubic spline model.
As shown, there was an increased risk for AF and stroke with
decreasing ABI values. A similar trend was observed for
increasing ABI values.
Discussion
In this analysis from MESA, we examined the association
between PAD and incident AF and stroke, separately. We also
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examined whether a potential association between PAD and
AF explained the known association between PAD and stroke.
Our study revealed 2 key ﬁndings. First, PAD is associated
with incident AF regardless of age, sex, race/ethnicity, and
cardiovascular risk factors. Second, our results suggest that
the known association between PAD and stroke, which also
was conﬁrmed in our study, is not mediated by AF.
A recent examination of data from the Women’s Health
Initiative Study has shown that PAD, which was ascertained
by self-reported history, is independently associated with
incident AF among postmenopausal women (HR 1.53, 95% CI
1.37 to 1.72).4 This result is similar to that observed in the
current study. Additionally, the racially and ethnically diverse
population of men and women in MESA increases the
generalizability of our results compared with the Women’s
Health Initiative Study. Also, we used ABI to deﬁne PAD
instead of self-reported history, which was used in the
Women’s Health Initiative Study. Considering that a small
number of patients with abnormal ABI values have symptoms
of PAD, our results provide a more accurate estimate of the
risk for AF associated with PAD.20
Several reports have described the association of PAD with
stroke.7–10 Our results conﬁrm these ﬁndings in MESA by
using ABI measurements. However, to our knowledge, no
studies have examined the effect of incident AF on the
association between PAD and stroke. Due to many shared risk
factors, we hypothesized that the risk of stroke among those
with PAD was mediated by AF. Our results do not support this
claim. This provides useful information to better understand
the underlying mechanisms which are needed to appropriately
Table 1. Baseline Characteristics of Study Participants Stratiﬁed by PAD (N=6568)
Characteristic PAD (n=774) No PAD (n=5794) P Value*
Age, mean (SD), years 67 (10) 61 (10) <0.0001
Male sex, % 282 (36) 2832 (49) <0.0001
Race/ethnicity, %
White 282 (36) 2237 (39)
Black 314 (41) 1487 (26) <0.0001
Chinese American 64 (8.3) 725 (13)
Hispanic 114 (15) 1345 (23)
Education, %
High school or less 337 (44) 2051 (35)
Some college 248 (32) 1623 (28) <0.0001
College or more 189 (24) 2120 (37)
Annual income, %
<$20 000 280 (36) 1471 (25)
$20 000 to $49 999 275 (36) 2028 (35) <0.0001
≥$50 000 219 (28) 2295 (40)
Body mass index, mean (SD) kg/m2 28 (5.9) 28 (5.4) 0.41
Current or former smoker, % 445 (57) 2803 (48) <0.0001
Diabetes, % 157 (20) 756 (13) <0.0001
Systolic blood pressure, mean (SD), mm Hg 136 (25) 125 (21) <0.0001
Total cholesterol, mean (SD), mg/dL 196 (38) 194 (35) 0.21
HDL cholesterol, mean (SD), mg/dL 52 (16) 51 (15) 0.043
Antihypertensive medications, % 386 (50) 2012 (35) <0.0001
Statins, % 166 (21) 793 (14) <0.0001
Aspirin, % 197 (25) 1349 (23) 0.18
Lipid-lowering medications, % 181 (23) 865 (15) <0.0001
hs-CRP, mean (SD), mg/L 5.0 (7.3) 3.6 (5.7) <0.0001
Left ventricular hypertrophy, % 31 (4.0) 216 (3.7) 0.70
HDL indicates high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; PAD, peripheral arterial disease; SD, standard deviation.
*Statistical signiﬁcance for continuous data was tested using Wilcoxon rank-sum procedure and for categorical data using the v2 test.
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target preventative interventions to reduce the burden of
stroke.
The association between PAD and AF is not completely
understood. Both conditions share several risk factors and are
associated with increased levels of inﬂammation and
platelet-mediated thrombosis.1–3,21,22 It is plausible that the
association of PAD with AF reﬂects an underlying state (eg,
increased levels of inﬂammation, thrombosis, and coagula-
tion) with a predisposition for both conditions to the inﬂuence
the development of the other. Further research is needed to
elucidate these underlying mechanisms.
Patients with a high burden of medial arterial calciﬁcation
have high ABI values, which represents a different patholog-
ical state compared with low ABI values.23 In our study, the
association of both low and high ABI values with AF was in the
same direction as the main model for PAD. This indicates that
PAD, regardless of the pathophysiological basis or pattern, is
associated with an increased risk for the development of AF.
Among diabetic patients, arterial stenosis and incompress-
ibility may have resulted in the misclassiﬁcation of PAD.24,25
Diabetes is present in 41% of patients with PAD, and the
risk for AF is increased by 40% in these patients.26,27 Diabetes
also has been associated with a 10% higher risk of subclavian
stenosis and a greater prevalence of subclinical episodic
AF.28,29 While a differential bias for AF cannot be ruled out,
the direction likely is toward the null. Furthermore, our
multivariable results were not substantively affected when
controlling for diabetes.
Several limitations of the current analysis should be
addressed. Incident AF cases were ascertained from hospi-
talization discharge records and inpatient Medicare claims
data using International Classiﬁcation of Disease, Ninth
Revision codes, which possibly resulted in misclassiﬁcation.
However, this method has been shown to have adequate
positive predictive value for the identiﬁcation of AF
events.30,31 Additionally, paroxysmal cases of AF potentially
were missed due to its time-dependent nature. This would
only make our results conservative because these missed AF
cases would be included in the non-AF group. Also, the actual
onset of AF cannot be precisely known, and cases may have
occurred before hospital admission in which the diagnosis
was conﬁrmed. Routine monitoring for AF was not performed
in MESA and therefore asymptomatic cases possibly were
missed. However, we do not know of any reason to suggest
that the resulting bias, if any, would have been differential in
Figure 1. Unadjusted cumulative incidence of AF by PAD
(N=6568). Cumulative incidence curves are different (log-rank
P<0.0001). Ankle-brachial index values of <1.0 or >1.4 deﬁned
PAD. AF indicates atrial ﬁbrillation; PAD, peripheral arterial
disease; y, years.
Table 2. Risk of AF With PAD
Subgroup Events/No. at Risk Model 1* HR (95% CI) P Value Model 2† HR (95% CI) P Value Interaction P Value‡
All 301/6568 1.7 (1.3 to 2.2) 0.0004 1.5 (1.1 to 2.0) 0.0041 —
Age, years§
<62 43/3218 2.2 (0.93 to 5.4) 0.071 1.8 (0.74 to 4.4) 0.20 0.79
≥62 258/3350 1.9 (1.4 to 2.5) <0.0001 1.7 (1.3 to 2.3) 0.0003
Sex
Female 115/3454 1.7 (1.1 to 2.6) 0.0098 1.6 (1.1 to 2.5) 0.028 0.64
Male 186/3114 1.6 (1.1 to 2.4) 0.012 1.5 (1.01 to 2.2) 0.043
Race/ethnicity
White 166/2519 1.6 (1.1 to 2.3) 0.022 1.5 (0.98 to 2.2) 0.064 0.71
Nonwhite 135/4049 1.8 (1.2 to 2.7) 0.0038 1.6 (1.04 to 2.4) 0.034
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; HR, hazard ratio; PAD, peripheral arterial disease.
†Adjusted for Model 1 covariates plus smoking status, systolic blood pressure, diabetes, body mass index, total cholesterol, high-density lipoprotein cholesterol, aspirin, antihypertensive
and lipid-lowering medications, high-sensitivity C-reactive protein levels, and left ventricular hypertrophy.
‡Interactions tested using Model 2.
§Dichotomized at the median age for study participants.
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nature, rather than merely reducing effect estimates toward
the null. PAD was deﬁned by ABI values <1.0 and >1.4
according to current guidelines.17 The association between
PAD and ABI may vary depending on the deﬁnition of
abnormal ABI (eg, <0.9).32 Hence, comparing our results with
other studies that use different deﬁnitions of abnormal ABI
should be done with caution. ABI values used in this analysis
were obtained during a single visit, and results may vary with
interval measurements.9 Differences in the measurement of
ABI may have posed another source of variability.33 However,
the measurements of ABI in the United States and in MESA
are standardized. Furthermore, the small number of AF cases
that occurred before stroke may have limited the power to
detect the mediating effect of AF on stroke. Similar to other
observational studies, we also acknowledge that residual
confounding remains a possibility.
In conclusion, we have shown that PAD, as deﬁned by
abnormal ABI values, is associated with an increased risk of
AF in MESA. Additionally, our results suggest that the
relationship between PAD and stroke is not mediated by AF.
A
B
Figure 2. Risk of AF (A) and stroke (B) with ABI. Each hazard ratio was computed with the median ABI
value of 1.12 as the referent group and was adjusted for age, sex, and race/ethnicity. Dotted lines
represent the 95% CI. The hazard ratio for AF is depicted in (A). The hazard ratio for stroke is depicted in (B).
ABI indicates ankle-brachial index; AF, atrial ﬁbrillation; CI, conﬁdence interval.




HR (95% CI) P Value
Model 1*† With
AF HR (95% CI) P Value
Model 2‡ HR
(95% CI) P Value
Model 2‡† With
AF HR (95% CI) P Value
No PAD 104/5794 1.0 — 1.0 — 1.0 — 1.0 —
PAD 36/774 2.0 (1.4 to 3.0) 0.0004 2.1 (1.4 to 3.0) 0.0003 1.7 (1.1 to 2.5) 0.015 1.7 (1.1 to 2.5) 0.011
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; HR, hazard ratio; PAD, peripheral arterial disease.
*Adjusted for age, sex, race/ethnicity, income, and education.
†AF adjusted as a time-dependent covariate.
‡Adjusted for Model 1 covariates plus smoking status, systolic blood pressure, diabetes, body mass index, total cholesterol, high-density lipoprotein cholesterol, aspirin, antihypertensive
and lipid-lowering medications, high-sensitivity C-reactive protein levels, and left ventricular hypertrophy.
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Further research is needed to examine the usefulness of ABI
to identify patients who have an increased risk for the
development of AF.
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